Compare Cassava Sciences Inc (FLNA) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Matson Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Matson Inc trades at $229 (market cap $6.81B). The key difference: Matson Inc is far larger — about 172.8× Cassava Sciences Inc's market cap, and Matson Inc pays a 0.67% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Matson Inc for 23 Days on average.
| FLNA | MATX | |
|---|---|---|
Market Cap | $39.40M | $6.81B |
Volume | 759,018 | 255,080 |
Sector | Health | Industrials |
52-Week High | $4.64 | $238.60 |
52-Week Low | $0.68 | $88.05 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | -$43.28M | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Matson (MATX) trades at $222.92, down 0.83% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $4.27 versus $3.79 expected, and maintains healthy profitability with a 13.41% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment toward the transportation services sector.
MATX presents a compelling investment case with solid earnings growth, attractive valuation metrics (P/E of 15.37), and strong analyst support (66.7% buy ratings). Key risks include freight market volatility and competitive pressures, but the company's raised full-year outlook and dividend payments provide stability. The stock offers potential upside with Wall Street analysts projecting 27.3% price target upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
